I somewhat share Baldwidx concerns that we may have a potential issue with NNZ-2591 development, being that we do not have complete control over what indications can be developed for NNZ-2591 on our own.From the NEU announcement 14/7/2023;
Neuren has an obligation not to develop NNZ-2591 or any other product for North America in an indication for which Acadia develops trofinetide, except for Phelan-McDermid, Pitt Hopkins, Angelman and Prader-Willi syndromes.
If Acadia decide to begin to developing trofinetide across an expansive range of syndromes how will that affect NNZ-2591's value?
I can't answer whether or not they can they do that, or whether they would they do that, or even if Acadia could afford to, however it certainly bares considering.
- Forums
- ASX - By Stock
- NEU
- ANAVEX MEETS ENDPOINTS PHASE2 RETT
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-138
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.65 |
Change
0.050(0.32%) |
Mkt cap ! $1.996B |
Open | High | Low | Value | Volume |
$15.64 | $15.93 | $15.61 | $1.830M | 116.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 17 | $15.64 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.65 | 138 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 48 | 15.700 |
10 | 374 | 15.690 |
5 | 542 | 15.680 |
6 | 446 | 15.670 |
3 | 375 | 15.660 |
Price($) | Vol. | No. |
---|---|---|
15.710 | 180 | 5 |
15.720 | 350 | 4 |
15.730 | 319 | 4 |
15.740 | 411 | 3 |
15.750 | 423 | 3 |
Last trade - 11.00am 15/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online